What is Letybo and how does it compare to Botox?

Letybo is a botulinum toxin formulation made by South Korean company Hugel Aesthetics that is already approved in multiple markets. While efficacy between toxin products is largely commoditized, Letybo differentiates through the K-TOX branding that leverages Korean aesthetic credentials and the company's direct US sales force for enhanced clinical support and physician relationships.

Why is Hugel building a direct sales force instead of using distributors?

A dedicated sales team allows Hugel to build direct physician relationships and provide clinical education rather than relying solely on distributor networks. This strategy is designed to compete against entrenched players like AbbVie/Allergan and Galderma by creating stronger prescriber loyalty through personalized support and engagement.

What does K-TOX branding mean for medspa owners?

K-TOX is Hugel's branded positioning that capitalizes on the global cachet of Korean beauty and cosmetic procedures. For medspa owners, this represents a new market entrant differentiating on aesthetic heritage rather than just price or rebates, which could shift competitive dynamics and potentially offer alternative toxin sourcing with Korean beauty credentials.

How does Hugel plan to compete against Allergan and Galderma?

Hugel is competing through a combination of a dedicated US direct sales force, clinical support, physician education, and the K-TOX branding angle that positions Korean aesthetic expertise. In a commoditized toxin market, the company is betting on relationship-building and differentiated positioning rather than competing primarily on rebate programs.

Is Letybo FDA approved in the United States?

Letybo is already approved in multiple markets globally, though the article does not specify current US FDA approval status. Hugel's escalation of US direct sales efforts suggests the company is actively pursuing or has secured US market access for Letybo.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

Hugel Builds US Direct Sales Force for Letybo, Launches K-TOX Campaign

South Korean toxin maker escalates stateside presence with dedicated field team and branded marketing push.

By Evan at Inside MedSpa · Jul 23, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Hugel Aesthetics is deploying a direct sales force in the US to drive Letybo adoption and rolling out a K-TOX campaign—a branded positioning effort that leans into Korean aesthetic credentials. The move signals serious commitment to compete against entrenched players like AbbVie/Allergan and Galderma in the North American market.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/hugel-expands-us-market-letybo-direct-sales/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Hugel Builds US Direct Sales Force for Letybo, Launches K-TOX Campaign

Share

Discussion

Leave a comment

By the time it's news, it's too late.